Luteolin mitigates potassium dichromate-induced nephrotoxicity, cardiotoxicity and genotoxicity through modulation of

Omolola Victoria Awoyomi1, Yemisi Dorcas Adeoye1, Ademola Adetokunbo Oyagbemi2

  • 1Federal College of Animal Health and Production Technology, Ibadan, Nigeria.

Insights

Luteolin, a potent antioxidant, demonstrated significant cardioprotective, nephroprotective, and antigenotoxic effects against potassium dichromate (K2Cr2O7) induced toxicity in rats by mitigating oxidative stress and inflammation.

Area of Science:

  • Toxicology
  • Pharmacology
  • Biochemistry

Background:

  • Environmental and occupational exposure to chromium compounds like potassium dichromate (K2Cr2O7) is linked to kidney disease due to oxidative stress, apoptosis, and inflammation.
  • These mechanisms contribute to nephrotoxicity and cardiotoxicity, highlighting the need for protective agents.

Purpose of the Study:

  • To evaluate the cardioprotective and nephroprotective effects of Luteolin, a natural antioxidant, against K2Cr2O7-induced toxicity in a rat model.
  • To investigate the impact of Luteolin on oxidative stress markers, blood pressure, and specific molecular indicators of kidney and cardiac injury.

Main Methods:

  • Forty healthy rats were divided into four groups: control, K2Cr2O7 exposure, and two groups pre-treated with different doses of Luteolin before K2Cr2O7 exposure.
  • Key parameters assessed included blood pressure, oxidative stress markers, nitric oxide levels, micronucleated polychromatic erythrocytes (MnPEs), and immunohistochemical analysis for kidney injury molecule (Kim-1), Nrf2, and cardiac troponin I.

Main Results:

  • Potassium dichromate (K2Cr2O7) administration elevated blood pressure, oxidative stress, and MnPEs frequency, while decreasing nitric oxide levels.
  • K2Cr2O7 exposure increased renal Kim-1 and cardiac troponin I expression, alongside decreased Nrf2 expression in both organs.
  • Luteolin pre-treatment normalized blood pressure, reduced oxidative stress, enhanced antioxidant capacity and nitric oxide levels, downregulated Kim-1 and cardiac troponin I, and upregulated Nrf2, while decreasing MnPEs frequency.

Conclusions:

  • Luteolin exhibits significant cardioprotective, nephroprotective, and antigenotoxic effects.
  • These protective actions are mediated through Luteolin's potent antioxidant and radical scavenging properties.
  • Luteolin represents a promising therapeutic agent for mitigating chromium-induced organ damage.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
1.7K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
559
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
606
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
857
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.4K